UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2015

OR

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             

Commission File Number: 001-35703

 

PUMA BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

77-0683487

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA 90024

(Address of principal executive offices) (Zip code)

(424) 248-6500

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨.

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

x

  

Accelerated filer

 

¨

 

 

 

 

Non-accelerated filer

 

¨  (Do not check if a smaller reporting company)

  

Smaller reporting company

 

¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ¨    No  x.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. 32,150,946 shares of Common Stock, par value $0.0001 per share, were outstanding as of April 30, 2015.

 

 

 

 

 


PUMA BIOTECHNOLOGY, INC.

- INDEX -

 

 

Page

PART I – FINANCIAL INFORMATION:

 

 

Item 1.

 

Financial Statements:

1

 

 

 

Condensed Consolidated Balance Sheets as of March 31, 2015 (Unaudited) and December 31, 2014

1

 

 

 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2015 and 2014, (Unaudited)

2

 

 

 

Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2015 and 2014 (Unaudited)

3

 

 

 

Condensed Consolidated Statement of Stockholders’ Equity for the Three Months Ended March 31, 2015 (Unaudited)

4

 

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2015 and 2014 (Unaudited)

5

 

 

 

Notes to Condensed Consolidated Financial Statements

6

 

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

14

 

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

20

 

Item 4.

 

Controls and Procedures

20

 

PART II – OTHER INFORMATION:

 

 

Item 1.

 

Legal Proceedings

21

 

Item 1A.

 

Risk Factors

21

 

Item 2.

 

Unregistered Sales of Equity Securities and Use of Proceeds

21

 

Item 3.

 

Defaults Upon Senior Securities

21

 

Item 4.

 

Mine Safety Disclosures

21

 

Item 5.

 

Other Information

21

 

Item 6.

 

Exhibits

22

 

Signatures

23

 

 

 


CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward looking. These forward-looking statements include, but are not limited to, statements about:

the development of our drug candidates, including when we expect to undertake, initiate and complete clinical trials of our product candidates;

the anticipated timing of regulatory filings;

the regulatory approval of our drug candidates;

our use of clinical research organizations and other contractors;

our ability to find collaborative partners for research, development and commercialization of potential products;

our ability to market any of our products;

our history of operating losses;

our expectations regarding our costs and expenses;

our anticipated capital requirements and estimates regarding our needs for additional financing;

our ability to compete against other companies and research institutions;

our ability to secure adequate protection for our intellectual property;

our ability to attract and retain key personnel; and

our ability to obtain adequate financing.

These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend” and similar words or phrases. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in them. Discussions containing these forward-looking statements may be found throughout this Quarterly Report on Form 10-Q, including, in Part I, the section entitled “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These forward-looking statements involve risks and uncertainties, including the risks discussed in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2014, that could cause our actual results to differ materially from those in the forward-looking statements. Such risks should be considered in evaluating our prospects and future financial performance. We undertake no obligation to update the forward-looking statements or to reflect events or circumstances after the date of this document.

 

 

 


Part I – FINANCIAL INFORMATION

Item 1. Financial Statements

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

 

 

March 31,

2015

(unaudited)

 

 

December 31,

2014

(Note 1)

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

155,466

 

 

$

38,539

 

Marketable securities

 

 

154,863

 

 

 

102,788

 

Prepaid expenses and other, current

 

 

6,357

 

 

 

6,292

 

Licensor receivable

 

 

 

 

 

1,760

 

Total current assets

 

 

316,686

 

 

 

149,379

 

Property and equipment, net

 

 

2,412

 

 

 

2,157

 

Prepaid expenses and other, long-term

 

 

9,811

 

 

 

10,007

 

Licensor receivable

 

 

1,760

 

 

 

 

Restricted cash

 

 

1,215

 

 

 

1,215

 

Total assets

 

$

331,884

 

 

$

162,758

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

12,608

 

 

$

14,997

 

Accrued expenses

 

 

13,469

 

 

 

29,444

 

Total current liabilities

 

 

26,077

 

 

 

44,441

 

Deferred rent

 

 

1,471

 

 

 

1,269

 

Total liabilities

 

 

27,548

 

 

 

45,710

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock - $.0001 par value;  100,000,000 shares authorized;  32,089,629 shares issued and outstanding at March 31, 2015 and 30,548,309 issued and outstanding at December 31, 2014

 

 

3

 

 

 

3

 

Additional paid-in capital

 

 

638,092

 

 

 

399,191

 

Receivables from the exercise of options

 

 

 

 

 

(835

)

Accumulated other comprehensive loss

 

 

(89

)

 

 

(95

)

Accumulated deficit

 

 

(333,670

)

 

 

(281,216

)

Total stockholders' equity

 

 

304,336

 

 

 

117,048

 

Total liabilities and stockholders' equity

 

$

331,884

 

 

$

162,758

 

See Accompanying Notes to the Condensed Consolidated Financial Statements

 

 

 

1

 


 

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands except share and per share data)

(unaudited)

 

 

 

 

Three Months Ended March 31,

 

 

 

2015

 

 

2014

 

Operating expenses:

 

 

 

 

 

 

 

 

General and administrative

 

$

7,871

 

 

$

3,525

 

Research and development

 

 

44,728

 

 

 

16,294

 

Totals

 

 

52,599

 

 

 

19,819

 

Loss from operations

 

 

(52,599

)

 

 

(19,819

)

Other income (expenses):

 

 

 

 

 

 

 

 

Interest income

 

 

123

 

 

 

46

 

Other income (expense)

 

 

22

 

 

 

(21

)

Totals

 

 

145

 

 

 

25

 

Net loss

 

$

(52,454

)

 

$

(19,794

)

Net loss applicable to common stock

 

$

(52,454

)

 

$

(19,794

)

Net loss per common share—basic and diluted

 

$

(1.66

)

 

$

(0.67

)

Weighted-average common shares outstanding—basic and diluted

 

 

31,588,315

 

 

 

29,567,071

 

 

 

See Accompanying Notes to the Condensed Consolidated Financial Statements

 

 

2

 


 

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended March 31,

 

 

 

2015

 

 

2014

 

Net loss

 

$

(52,454

)

 

$

(19,794

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities

 

 

6

 

 

 

(9

)

Comprehensive loss

 

$

(52,448

)

 

$

(19,803

)

See Accompanying Notes to the Condensed Consolidated Financial Statements

 

 

 

3

 


 

 

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY

FOR THE THREE MONTHS ENDED MARCH 31, 2015

(in thousands except share data)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Additional

Paid-in

Capital

 

 

Receivables

from the

Exercises of

Options

 

 

Accumulated

Other

Comprehensive

Income (Loss)

 

 

Accumulated

Deficit

 

 

Total

 

Balance at December 31, 2014

 

 

30,548,309

 

 

$

3

 

 

$

399,191

 

 

$

(835

)

 

$

(95

)

 

$

(281,216

)

 

$

117,048

 

Stock option compensation

 

 

 

 

 

 

 

 

20,103

 

 

 

 

 

 

 

 

 

 

 

 

20,103

 

Exercises of stock options

 

 

386,355

 

 

 

 

 

 

13,602

 

 

 

835

 

 

 

 

 

 

 

 

 

14,437

 

Issuance of performance shares

 

 

4,965

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issuance of shares of common stock through equity placement at $190.00 per share, net of issuance costs

 

 

1,150,000

 

 

 

 

 

 

205,196

 

 

 

 

 

 

 

 

 

 

 

 

205,196

 

Unrealized gain on available for sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6

 

 

 

 

 

 

6

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(52,454

)

 

 

(52,454

)

Balance at March 31, 2015

 

 

32,089,629

 

 

$

3

 

 

$

638,092

 

 

$

-

 

 

$

(89

)

 

$

(333,670

)

 

$

304,336

 

 

See Accompanying Notes to the Condensed Consolidated Financial Statements

 

 

4

 


 

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended March 31,

 

 

 

2015

 

 

2014

 

Operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(52,454

)

 

$

(19,794

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

180

 

 

 

133

 

Build-out allowance received from landlord

 

 

179

 

 

 

 

Stock option expense

 

 

20,103

 

 

 

5,163

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Licensor receivable

 

 

 

 

 

(3,483

)

Prepaid expenses and other

 

 

131

 

 

 

(145

)

Accounts payable

 

 

(2,389

)

 

 

4,500

 

Accrued expenses

 

 

(15,975

)

 

 

(3,528

)

Accrual of deferred rent

 

 

202

 

 

 

107

 

Net cash used in operating activities

 

 

(50,023

)

 

 

(17,047

)

Investing activities:

 

 

 

 

 

 

 

 

Purchase of property and equipment

 

 

(435

)

 

 

(214

)

Expenditures for leasehold improvements

 

 

(179

)

 

 

(4

)

Purchase of available-for-sale securities

 

 

(104,838

)

 

 

 

Sale/maturity of available-for-sale securities

 

 

52,769

 

 

 

8,161

 

Net cash (used in) provided by investing activities

 

 

(52,683

)

 

 

7,943

 

Financing activities:

 

 

 

 

 

 

 

 

Net proceeds from issuance of common stock

 

 

205,196

 

 

 

129,440

 

Net proceeds from exercise of options

 

 

14,437

 

 

 

 

Net cash provided by financing activities

 

 

219,633

 

 

 

129,440

 

Net increase in cash and cash equivalents

 

 

116,927

 

 

 

120,336

 

Cash and cash equivalents, beginning of period

 

 

38,539

 

 

 

43,044

 

Cash and cash equivalents, end of period

 

$

155,466

 

 

$

163,380

 

 

See Accompanying Notes to the Condensed Consolidated Financial Statements

 

 

5

 


 

PUMA BIOTECHNOLOGY, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1—Business and Basis of Presentation:

Business:

Puma Biotechnology, Inc., or Puma, is a biopharmaceutical company based in Los Angeles, California. References in these Notes to Condensed Consolidated Financial Statements to the “Company” refer to Puma Biotechnology, Inc., a private Delaware company formed on September 15, 2010, or Private Puma, for periods prior to the merger of Private Puma with Public Puma (as defined below), which took place on October 4, 2011, or the Merger, and Puma Biotechnology, Inc., a Delaware company formed on April 27, 2007, and formerly known as Innovative Acquisitions Corp., or Public Puma, for periods following the Merger. The Company is a biopharmaceutical company with a focus on the acquisition, development and commercialization of innovative products to enhance cancer care. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

In November 2012, the Company established and incorporated Puma Biotechnology Ltd., a wholly owned subsidiary, for the sole purpose of serving as Puma’s legal representative in the United Kingdom and the European Union in connection with Puma’s clinical trial activity in those countries.

Basis of Presentation:

The Company is initially focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2.  The Company has reported a net loss of approximately $52.5 million and negative cash flows from operations of approximately $50.0 million for the three months ended March 31, 2015. Management believes that the Company will continue to incur net losses and negative net cash flows from operating activities through the drug development process.

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial information.  Accordingly, the financial statements do not include all information and footnotes required by GAAP for complete annual financial statements.  In the opinion of management, the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation.  Interim operating results are not necessarily indicative of results that may be expected for the year ending December 31, 2015, or for any subsequent period.  These unaudited condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014.  The condensed consolidated balance sheet at December 31, 2014, has been derived from the audited consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

The Company’s continued operations will depend on its ability to raise funds through various potential sources, such as equity and debt financing. Through March 31, 2015, the Company’s financing was primarily through public offerings of Company common stock and private equity placements. The Company sold additional shares of its common stock through an underwritten public offering in January 2015 (see Note 6).  As a result, the Company received net proceeds of approximately $205.2 million.  Given the current and desired pace of clinical development of its product candidates, management believes that the cash and cash equivalents and marketable securities on hand at March 31, 2015, are sufficient to fund clinical development through 2016 and into 2017. The Company may need additional financing until it can achieve profitability, if ever.  There can be no assurance that additional capital will be available on favorable terms or at all or that any additional capital that the Company is able to obtain will be sufficient to meet its needs.  If it is unable to raise additional capital, the Company could likely be forced to curtail desired development activities, which will delay the development of its product candidates.

 

 

6

 


 

Note 2—Significant Accounting Policies:

The significant accounting policies followed in the preparation of these condensed consolidated financial statements are as follows:

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include accrued expenses for the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates used to record accrued expenses and to value the stock-based compensation will occur in the near term.

Principles of Consolidation:

The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents:

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.

Licensor Receivable:

The Pfizer, Inc., or Licensor, receivable represents the remaining external “out of pocket” clinical trial costs in excess of an agreed upon “cap” for clinical trials that were ongoing at the time the licensing agreement with the Licensor was reached. In July 2014, the license agreement was amended to make the Company solely responsible for the expenses incurred or accrued in conducting the ongoing legacy clinical trials after December 31, 2013, and to fix the future royalty rate that must be paid to the Licensor upon commercialization in the low to mid-teens. The Company has not established a reserve against this receivable as it is deemed to be fully collectible and is considered non-current as of March 31, 2015.

Investment Securities:

The Company classifies all investment securities (short term and long term) as available-for-sale, as the sale of such securities may be required prior to maturity to implement management’s strategies. These securities are carried at fair value, with the unrealized gains and losses, reported as a component of accumulated other comprehensive income (loss) in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. A decline in the market value of any available-for-sale security below cost that is determined to be other than temporary results in a revaluation of its carrying amount to fair value. The impairment is charged to earnings and a new cost basis for the security is established. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method. Interest income is recognized when earned.

Assets Measured at Fair Value on a Recurring Basis:

Accounting Standards Codification, or “ASC”, 820, Fair Value Measurement, or ASC 820, provides a single definition of fair value and a common framework for measuring fair value as well as new disclosure requirements for fair value measurements used in financial statements. Under ASC 820, fair value is determined based upon the exit price that would be received by a company to sell an asset or paid by a company to transfer a liability in an orderly transaction between market participants, exclusive of any transaction costs. Fair value measurements are determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company uses the most advantageous market, which is the market from which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement. ASC 820 creates a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest.

7

 


 

 

Level 1:

  

Quoted prices in active markets for identical assets or liabilities.

 

 

 

Level 2:

  

Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

 

 

 

Level 3:

  

Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

 

Following are the major categories of assets measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3) (in thousands):

 

March 31, 2015

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents

 

$

146,906

 

 

$

 

 

$

 

 

$

146,906

 

Agency bond

 

 

 

 

 

5,002

 

 

 

 

 

 

5,002

 

Marketable securities - U.S. government

 

 

 

 

 

11,518

 

 

 

 

 

 

11,518

 

Marketable securities - corporate bonds

 

 

 

 

 

138,343

 

 

 

 

 

 

138,343

 

 

 

$

146,906

 

 

$

154,863

 

 

$

 

 

$

301,769

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2014

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Cash equivalents

 

$

20,874

 

 

$

 

 

$

 

 

$

20,874

 

Marketable securities - U.S. government

 

 

 

 

 

11,496

 

 

 

 

 

 

11,496

 

Marketable securities - corporate bonds

 

 

 

 

 

91,292

 

 

 

 

 

 

91,292

 

 

 

$

20,874

 

 

$

102,788

 

 

$

 

 

$

123,662

 

 

The Company’s investments in agency bonds, corporate bonds and U.S. government securities are exposed to price fluctuations. The fair value measurements for agency bonds, corporate bonds and U.S. government securities are based upon the quoted prices of similar items in active markets multiplied by the number of securities owned, exclusive of any transaction costs and without any adjustments to reflect discounts that may be applied to selling a large block of securities at one time.

Concentration of Risk:

Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company’s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at March 31, 2015, were approximately $156.8 million. The Company does not believe it is exposed to any significant credit risk due to the quality of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Corporation and Moody’s Investors Service at the time of purchase.

Property and Equipment:

Property and equipment are recorded at cost and depreciated over estimated useful lives ranging from three to five years using the straight-line method. Leasehold improvements are recorded at cost and amortized over the shorter of their useful lives or the term of the lease by use of the straight-line method. Maintenance and repair costs are charged to operations as incurred.

The Company assesses the impairment of long-lived assets, primarily property and equipment, whenever events or changes in business circumstances indicate that carrying amounts of the assets may not be fully recoverable. When such events occur, management determines whether there has been impairment by comparing the asset’s carrying value with its fair value, as measured by the anticipated undiscounted net cash flows of the asset. Should impairment exist, the asset is written down to its estimated fair value. The Company has not recognized any impairment losses through March 31, 2015.

Research and Development Expenses:

Research and development expenses are charged to operations as incurred. The major components of research and development costs include clinical manufacturing costs, clinical trial expenses, consulting and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials, and allocations of various overhead costs. Clinical trial expenses include, but are not limited to, investigator fees, site costs, comparator drug costs, and clinical research organization, or CRO, costs. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing

8

 


 

development of potential products. The financial terms of these agreements are subject to negotiation and variations from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients and the completion of portions of the clinical trial or similar conditions. The Company’s accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical trial sites, cooperative groups and CROs. The objective of the Company’s accrual policy is to match the recording of expenses in the condensed consolidated financial statements to the actual services received and efforts expended. As actual costs become known, the Company adjusts its accruals in that period.

In instances where the Company enters into agreements with third parties for clinical trials and other consulting activities, upfront amounts are recorded to prepaid expenses and other in the accompanying condensed consolidated balance sheets and expensed as services are performed or as the underlying goods are delivered. If the Company does not expect the services to be rendered or goods to be delivered, any remaining capitalized amounts for non-refundable upfront payments are charged to expense immediately. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables.

Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development costs.

Stock-Based Compensation:

Stock option awards:

ASC 718, Compensation-Stock Compensation, or ASC 718, requires the fair value of all share-based payments to employees, including grants of stock options, to be recognized in the statement of operations over the requisite service period. Under ASC 718, employee option grants are generally valued at the grant date and those valuations do not change once they have been established. The fair value of each option award is estimated on the grant date using the Black-Scholes Option Pricing Method. As allowed by ASC 718 for companies with a short period of publicly traded stock history, the Company’s estimate of expected volatility is based on the average expected volatilities of a sampling of seven companies with similar attributes to the Company, including industry, stage of life cycle, size and financial leverage. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant valuation. Option forfeitures are calculated when the option is granted to reduce the option expense to be recognized over the life of the award and updated upon receipt of further information as to the amount of options expected to be forfeited. The option expense is “trued-up” upon the actual forfeiture of a stock option grant. Due to its limited history, the Company uses the simplified method to determine the expected life of the option grants.

Performance shares:

The performance shares are valued on the grant date and the fair value of the performance award is equal to the market price of the Company’s common stock on the grant date. The performance share expense is recognized based on the Company’s estimate of a range of probabilities that the Company’s closing common stock price on the vesting dates will be lower or higher than the Company’s common stock price on the grant date. Based on the range of probabilities, the expense is calculated and recognized over the three-year vesting period.

Net Loss per Common Share:

Basic net loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the periods presented as required by ASC 260, Earnings per Share. Diluted earnings per common share are the same as basic earnings per share because the assumed exercise of the Company’s outstanding options are anti-dilutive. For the three months ended March 31, 2015, potentially dilutive securities excluded from the calculations were 3,832,073 shares issuable upon exercise of options, 18,942 shares issuable as performance awards and 2,116,250 shares issuable upon exercise of a warrant. For the three months ended March 31, 2014, potentially dilutive securities excluded from the earnings per common share calculation were 3,059,849 issuable upon exercise of options, 28,411 issuable as performance shares and 2,116,250 shares issuable upon exercise of a warrant.

Deferred Rent:

The Company has entered into operating lease agreements for its corporate offices in Los Angeles and South San Francisco that contain provisions for future rent increases, leasehold improvement allowances and rent abatements. The Company records monthly rent expense equal to the total of the payments due over the lease term, divided by the number of months of the lease term. The difference between the rent expense recorded and the amount paid is credited or charged to deferred rent, which is reflected as a separate line item in the accompanying condensed consolidated balance sheets. Additionally, the Company recorded as deferred rent the cost of the leasehold improvements paid by the landlord, which is amortized on a straight-line basis over the term of the lease.

9

 


 

Issuance of Common Stock Upon Exercise of Stock Option Grants:

When a stock option grant or partial stock option grant is exercised, the Company notifies its transfer agent to release the required number of common stock shares from the reserve for the Company’s 2011 Incentive Award Plan. The Company records the transaction for the cash received and the issuance of common shares. Should there be a delay in the cash receipts due to the settlement period, the Company records a receivable from the exercise of an option as part of stockholders’ equity on the condensed consolidated balance sheet.

Recently Issued Accounting Standards

 

 In August 2014, the Financial Accounting Standards Board, or the FASB, issued guidance requiring management to evaluate on a regular basis whether any conditions or events have arisen that could raise substantial doubt about the entity’s ability to continue as a going concern. The guidance (1) provides a definition for the term “substantial doubt,” (2) requires an evaluation every reporting period, interim periods included, (3) provides principles for considering the mitigating effect of management’s plans to alleviate the substantial doubt, (4) requires certain disclosures if the substantial doubt is alleviated as a result of management’s plans, (5) requires an express statement, as well as other disclosures, if the substantial doubt is not alleviated, and (6) requires an assessment period of one year from the date the financial statements are issued. The standard is effective for the Company’s reporting year beginning January 1, 2017 and early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.

 

In May 2014, the FASB issued guidance for revenue recognition for contracts, superseding the previous revenue recognition requirements, along with most existing industry-specific guidance. The guidance requires an entity to review contracts in five steps: (1) identify the contract, (2) identify performance obligations, (3) determine the transaction price, (4) allocate the transaction price, and (5) recognize revenue. The new standard will result in enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue arising from contracts with customers. The standard is effective for our reporting year beginning January 1, 2017 and early adoption is not permitted. The Company is currently evaluating the impact, if any, that this standard will have on its consolidated financial statements.

In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities, or ASU No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as development stage entities ( Topic 915 ). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and stockholder equity.  For public entities, these amendments begin to be effective for periods after December 31, 2014.  Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915.  The Company adopted this standard on December 31, 2014, and it did not have a material impact on its consolidated financial statements.

 

 

 

Note 3—Prepaid Expenses and Other:

Prepaid expenses and other consisted of the following (in thousands):

 

 

March 31, 2015

 

 

December 31, 2014

 

Current:

 

 

 

 

 

 

 

 

CRO services

 

$

2,486

 

 

$

2,451

 

Other clinical development

 

 

2,757

 

 

 

2,525

 

Insurance

 

 

800

 

 

 

1,007

 

Other

 

 

314

 

 

 

309

 

 

 

 

6,357

 

 

 

6,292

 

Long-term:

 

 

 

 

 

 

 

 

CRO services

 

 

6,290

 

 

 

6,352

 

Other clinical development

 

 

3,352

 

 

 

3,464

 

Insurance

 

 

113

 

 

 

130

 

Other

 

 

56

 

 

 

61

 

 

 

 

9,811

 

 

 

10,007

 

Totals

 

$

16,168

 

 

$

16,299

 

 

10

 


 

 

Note 4—Property and Equipment:

Property and equipment consisted of the following (in thousands):

Property and Equipment:

 

March 31, 2015

 

 

December 31, 2014

 

Leasehold improvements

 

$

1,438

 

 

$

1,217

 

Computer equipment

 

 

1,315

 

 

 

1,272

 

Telephone equipment

 

 

148

 

 

 

145

 

Furniture and fixtures

 

 

1,016

 

 

 

848

 

 

 

 

3,917

 

 

 

3,482

 

Less: accumulated depreciation and amortization

 

 

(1,505

)

 

 

(1,325

)

Totals

 

$

2,412

 

 

$

2,157

 

 

 

Note 5—Accrued Expenses:

Accrued expenses consisted of the following (in thousands):

 

 

March 31, 2015

 

 

December 31, 2014

 

Accrued CRO/licensor services

 

$

6,194

 

 

$

7,764

 

Accrued other clinical development

 

 

3,787

 

 

 

2,541

 

Accrued legal fees

 

 

357

 

 

 

195

 

Accrued compensation

 

 

3,040

 

 

 

2,449

 

Payroll taxes withheld for options exercised

 

 

 

 

 

16,414

 

Other

 

 

91

 

 

 

81

 

Totals

 

$

13,469

 

 

$

29,444

 

Accrued CRO/licensor services represent the Company’s estimate of such costs as of March 31, 2015, and will be adjusted in the period the actual costs become known. Accrued compensation includes estimated bonus and earned but unused vacation for full-time employees. When actual performance bonuses are paid out to employees on the employee’s anniversary of hire, the bonus expense will be adjusted to reflect the actual expense for the year. Additionally, vacation is accrued at the rate the employee earns vacation and reduced as vacation is used by the employee.

 

 

Note 6—Stockholders’ Equity:

Common Stock:

January 2015 Common Stock Offering. On January 21, 2015, the Company entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC, as representatives of several underwriters, providing for the offer and sale in a firm-commitment underwritten public offering of 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, at a price of $190.00 per share, less the underwriting discount. The underwriters exercised the option granted to the underwriters to purchase an additional 150,000 shares of Company common stock from the Company at $190.00 per share, less the underwriting discount. The transaction was completed on January 27, 2015; the Company received net proceeds of approximately $205.2 million, which is comprised of gross proceeds of approximately $218.5 million, offset by the underwriting discount and offering expenses of $13.3 million payable by the Company.

Stock-Based Compensation:

The Company’s 2011 Incentive Award Plan, or the 2011 Plan, was adopted by the Board of Directors and stockholders of the Company on September 15, 2011.  An amendment to the 2011 Plan, or the 2011 Plan Amendment, was adopted by the Board of Directors on June 4, 2014, and the stockholders of the Company on June 10, 2014.    The 2011 Plan Amendment increased the number of shares reserved from 3,529,412 to 6,529,412.  Pursuant to the amended 2011 Plan (referred to hereafter as the 2011 Plan), the Company may grant incentive stock options and nonqualified stock options, as well as other forms of equity-based compensation such as performance shares. Incentive stock options may be granted only to employees, while consultants, employees, officers and directors are eligible for the grant of nonqualified options under the 2011 Plan. The maximum term of stock options granted under the 2011 Plan is 10 years. The exercise price of incentive stock options granted under the 2011 Plan must be at least equal to the fair value of such shares on the date of grant. The performance shares are valued at market value less par value and vest over three years, with the number of shares to be issued determined by the market price on the vesting date. The maximum number of shares issuable pursuant to a performance share award is established on the grant date.

11

 


 

Employee stock-based compensation for the three months ended March 31, 2015 and 2014, were as follows (in thousands, except share and per share data):

 

 

 

2015

 

 

2014

 

 

Stock-based compensation:

 

 

 

 

 

 

 

 

 

Options -

 

 

 

 

 

 

 

 

 

Research and development, or R&D

 

$

15,254

 

 

$

3,226

 

 

General and administrative, or G&A

 

 

4,704

 

 

 

1,341

 

 

Performance shares: R&D

 

 

145

 

 

 

596

 

 

Total share-based compensation expense

 

$

20,103

 

 

$

5,163

 

 

Impact on basic and diluted net loss per share

 

$

0.64

 

 

$

0.17

 

 

Weighted average shares (basic and diluted)

 

 

31,588,315

 

 

 

29,567,071

 

 

 

Performance Shares:

During January 2014, performance share awards were granted to certain employees that provide for a maximum of 28,411 common stock shares to be issued. These shares vest over three years on the first, second and third anniversary of December 15, 2013. On each vesting date, if the Company’s closing common stock price is equal to $102.46 per share, one-third of the 28,411 shares will be awarded. If the Company’s closing common stock price is either lesser or greater than $102.46 per share, the number of common stock shares to be issued will be adjusted to be less than one-third of the 28,411 shares. No shares will be awarded if the Company’s closing common stock price is less than $47.53 per share at the vesting dates. The performance shares are valued on the grant date and the fair value of the performance award is equal to the market price of the Company’s common stock on the grant date. The performance share expense is recognized based on the Company’s estimate of a range of probabilities that the Company’s closing common stock price will be lower or higher than $102.46 on the vesting dates. Based on the range of probabilities, the expense is calculated and recognized over the three-year vesting period. On December 15, 2014, the first vesting occurred and the calculations were performed.  As a result, 4,965 shares of common stock were issued to the employees and 4,504 performance shares were cancelled.

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Grant-Date

 

Performance shares

 

Shares

 

 

Fair Value

 

Nonvested shares at December 31, 2014

 

 

18,942

 

 

$

102.46

 

Granted

 

 

 

 

 

 

Vested/Issued

 

 

 

 

 

 

Cancelled

 

 

 

 

 

 

Nonvested shares at March 31, 2015

 

 

18,942

 

 

$

102.46

 

Stock Options:

The fair value of options granted to employees was estimated using the Black-Scholes Option Pricing Method (see Note 2—Significant Accounting Policies) with the following weighted-average assumptions used during the three months ended March 31, 2015 and 2014:

 

 

 

2015

 

 

2014

 

 

Dividend yield

 

 

0.0

%

 

 

0.0

%

 

Expected volatility

 

 

63.1

%

 

 

81.3

%

 

Risk-free interest rate

 

 

1.6

%

 

 

1.8

%

 

Expected life in years

 

 

5.85

 

 

 

5.85

 

 

12

 


 

 

Activity with respect to options granted under the 2011 Plan is summarized as follows:

 

 

 

Shares

 

 

Weighted

Average

Exercise

Price

 

 

Weighted Average Remaining

Contractual Term (years)

 

 

Aggregate

Intrinsic Value

(in thousands)

 

Outstanding at December 31, 2014

 

 

3,978,126

 

 

$

89.55

 

 

 

8.7

 

 

$

431,635

 

Granted

 

 

270,500

 

 

$

218.13

 

 

 

9.5

 

 

 

 

Forfeited

 

 

(30,198

)

 

$

146.50

 

 

 

 

 

 

 

Exercised

 

 

(386,355

)

 

$

35.27

 

 

 

 

 

$

62,707

 

Outstanding at March 31, 2015

 

 

3,832,073

 

 

$

103.65

 

 

 

8.6

 

 

$

513,719

 

Unvested at March 31, 2015

 

 

2,523,156

 

 

$

145.01

 

 

 

9.2

 

 

$

236,086

 

Exercisable at March 31, 2015

 

 

1,308,917

 

 

$

23.91

 

 

 

7.5

 

 

$

277,748

 

 

At March 31, 2015, total estimated unrecognized employee compensation cost related to non-vested stock options and performance shares granted prior to that date were approximately $200.0 million and $0.8 million, respectively. These unrecognized expenses are expected to be recognized over a weighted-average period of 2.3 years for stock options and 1.3 years for performance shares. The weighted-average grant date fair value of options granted during the three months ended March 31, 2015 and 2014, were $125.41 per share and $73.89 per share, respectively.

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Grant-Date

 

Stock options

 

Shares

 

 

Fair Value

 

Nonvested shares at December 31, 2014

 

 

2,591,565

 

 

$

81.33

 

Granted

 

 

270,500

 

 

 

125.41

 

Vested/Issued

 

 

(308,711

)

 

 

44.13

 

Forfeited

 

 

(30,198

)

 

 

88.17

 

Nonvested shares at March 31, 2015

 

 

2,523,156

 

 

$

90.53

 

 

 

 

Note 7—401(k) Savings Plan:

 

During 2012, the Company adopted a 401(k) savings plan for the benefit of its employees. The Company is required to make matching contributions to the 401(k) plan equal to 100% of the first 3% of wages deferred by each participating employee and 50% on the next 2% of wages deferred by each participating employee. The Company incurred expenses for employer matching contributions of approximately $0.2 million and $0.1 million for the three months ended March 31, 2015 and 2014, respectively.

 

 

 

 

 

13

 


 

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included in Item 1 in this Quarterly Report on Form 10-Q. The following discussion should also be read in conjunction with our audited consolidated financial statements and the notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2014.

Unless otherwise provided in this Quarterly Report, references to the “Company,” “we,” “us,” and “our” refer to Puma Biotechnology, Inc., a Delaware corporation, together with its wholly-owned subsidiary, Puma Biotechnology Ltd.

Overview

We are a biopharmaceutical company based in Los Angeles, California with a focus on the acquisition, development and commercialization of innovative products to enhance cancer care. We aim to acquire proprietary rights to these products, by license or otherwise, fund their research and development, or R&D, and bring the products to market. Our efforts and resources to date have been focused primarily on acquiring and developing our pharmaceutical technologies, raising capital and recruiting personnel. We have had no product sales to date and we will have no product sales until we receive approval from the United States Food and Drug Administration, or FDA, or equivalent foreign regulatory bodies to begin selling our pharmaceutical candidates. Developing pharmaceutical products, however, is a lengthy and very expensive process. Assuming we do not encounter any unforeseen safety issues during the course of developing our product candidates, we do not expect to receive approval of a product candidate until approximately 2016.

We currently license the rights to three drug candidates:

PB272 (neratinib (oral)), which we are developing for the treatment of patients with human epidermal growth factor receptor type 2, or HER2, positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation;

PB272 (neratinib (intravenous)), which we are developing for the treatment of patients with advanced cancer; and

PB357, which we believe can serve as a backup compound to PB272, and which we are evaluating for further development.

A large portion of our expenses to date have been related to the clinical development of our lead product candidate, PB272 (neratinib (oral)), and the transition of the neratinib program from Pfizer, Inc., or the Licensor. Additionally, our expenses to date have been related to hiring staff, commencing company-sponsored clinical trials and the build out of our corporate infrastructure. As we proceed with clinical development of PB272 (neratinib (oral)), and as we further develop PB272 (neratinib (intravenous)), and PB357, our second and third product candidates, respectively, we expect our R&D expenses and expenses related to our third-party contractors will continue to increase.

To the extent we are successful in acquiring additional product candidates for our development pipeline, our need to finance R&D will increase. Accordingly, our success depends not only on the safety and efficacy of our product candidates, but also on our ability to finance product development. Our major sources of working capital have been proceeds from public offerings of our common stock and sales of our common stock in private placements.

Critical Accounting Policies

As of the date of the filing of this quarterly report, we believe there have been no material changes to our critical accounting policies and estimates during the three months ended March 31, 2015, from our accounting policies at December 31, 2014, as reported in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

Summary of Expenses

General and administrative, or G&A, expenses consist primarily of salaries and related personnel costs (including stock-based compensation expense), professional fees, business insurance, rent, general legal activities, and other corporate expenses.

R&D expenses consist primarily of CRO costs, other clinical development costs and salaries and related personnel costs (including stock-based compensation expense) and include costs associated with services provided by consultants who conduct clinical services on our behalf and contract organizations for manufacturing of clinical materials. We expense our R&D costs as they are incurred.

14

 


 

Results of Operations

Three Months Ended March 31, 2015 Compared to Three Months Ended March 31, 2014

General and administrative expenses:

For the three months ended March 31, 2015, G&A expenses were approximately $7.9 million, compared to approximately $3.5 million for the three months ended March 31, 2014. G&A expenses for the three months ended March 31, 2015 and 2014 were as follows:

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

Annual percentage change

 

(in thousands)

 

2015

 

 

2014

 

 

2015/2014

 

Payroll and related costs

 

$

1,033

 

 

$

751

 

 

 

37.5

%

Professional fees and expenses

 

 

974

 

 

 

589

 

 

 

65.4

%

Facility and equipment costs

 

 

551

 

 

 

417

 

 

 

32.1

%

Employee stock-based compensation expense

 

 

4,704

 

 

 

1,341

 

 

 

250.8

%

Other

 

 

609

 

 

 

427

 

 

 

42.6

%

 

 

$

7,871

 

 

$

3,525

 

 

 

123.3

%

 

For the three months ended March 31, 2015, G&A expenses increased approximately $4.4 million compared to the same period in 2014.  Approximately $3.4 million of this increase is related to stock-based compensation expense, which has increased as a result of our increased headcount, as well as the increase in our stock price per share which affects the valuation of new grants.  The remaining G&A increase for the three months ended March 31, 2015, compared to the same period in 2014, is approximately $1.0 million.  Of this, payroll and related costs increased approximately $0.3 million for the three months ended March 31, 2015, compared to the same period in 2014, as administrative headcount increased to 15 from 13 to support our corporate growth.  Professional fees and expenses increased approximately $0.4 million for the three months ended March 31, 2015, compared to the same period in 2014.  Professional fees and expenses consist of legal, auditing and consulting fees for compliance with the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley, and investor relations.  Facility and equipment costs for the three months ended March 31, 2015, increased only marginally when compared to the same period in 2014.  We recently leased additional suites in our Los Angeles and South San Francisco office locations to support the overall growth of the company and therefore expect our facility costs to increase.  Additionally, we expect payroll and related costs and professional fees and expenses to continue to increase as we prepare to support the Company’s activities related to the filing of a New Drug Application, or NDA, with the FDA during the first quarter of 2016 and as we prepare for commercialization.

Research and development expenses:

For the three months ended March 31, 2015, R&D expenses were approximately $44.7 million, compared to approximately $16.3 million for the three months ended March 31, 2014. R&D expenses for the three months ended March 31, 2015 and 2014 were as follows:

 

Research and development expenses

 

 

 

 

 

 

 

 

 

Annual percentage change

 

(in thousands)

 

2015

 

 

2014

 

 

2015/2014

 

Outside CRO/licensor services

 

$

11,405

 

 

$

3,931

 

 

 

190.1

%

Outside other clinical development

 

 

10,031

 

 

 

3,747

 

 

 

167.7

%

Internal regulatory affairs and quality assurance

 

 

1,977

 

 

 

1,610

 

 

 

22.8

%

Internal clinical development

 

 

5,626

 

 

 

2,997

 

 

 

87.7

%

Internal chemical manufacturing

 

 

290

 

 

 

187

 

 

 

55.1

%

Employee stock-based compensation

 

 

15,399

 

 

 

3,822

 

 

 

302.9

%

 

 

$

44,728

 

 

$

16,294

 

 

 

174.5

%

 

For the three months ended March 31, 2015, R&D expenses increased approximately $28.4 million compared to the same period in 2014. Approximately $11.6 million of this increase is related to the increase in stock-based compensation expense which has increased as a result of our increased headcount as well as the increase in our stock price per share which affects the valuation of new grants.  The remaining increase is approximately $16.8 million.  Approximately $7.5 million of this increase is related to outside CRO/licensor services, which have increased as a result of our preparation to file an NDA for our lead product candidate and additional late-stage and early-stage studies for additional potential indications of neratinib.   Approximately $6.2 million of this increase is an increase in outside other clinical development resulting from increases of approximately $1.9 million for clinical drug supply and manufacturing, approximately $2.9 million for clinical services and consulting, and approximately $1.4 million for pre-clinical and toxicity studies.  Internal clinical development, internal regulatory affairs and quality assurance, and internal chemical manufacturing accounted for the remaining approximately $3.1 million increase in R&D expenses.  This increase represents an increase in full-time R&D headcount to 107 from 73 for the three months ended March 31, 2015, compared to the same period in 2014.  

15

 


 

We expect R&D expenses to continue to increase as we recognize the additional expenses associated with the legacy clinical trials and as we hire additional R&D employees during the remainder of 2015 and into 2016 to support the filing of an NDA with the FDA and a Marketing Authorization Application with the European Medicines Agency.

While expenditures on current and future clinical development programs, particularly our PB272 program, are expected to be substantial and to increase, they are subject to many uncertainties, including the results of clinical trials and whether we develop any of our drug candidates with a partner or independently. As a result of such uncertainties, we cannot predict with any significant degree of certainty the duration and completion costs of our research and development projects or whether, when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. The duration and cost of clinical trials may vary significantly over the life of a project as a result of unanticipated events arising during clinical development and a variety of other factors, including:

the number of trials and studies in a clinical program;

the number of patients who participate in the trials;

the number of sites included in the trials;

the rates of patient recruitment and enrollment;

the duration of patient treatment and follow-up;

the costs of manufacturing our drug candidates; and

the costs, requirements, timing of, and ability to secure regulatory approvals.

Interest income:

For the three months ended March 31, 2015, we recognized approximately $123,000 in interest income compared to approximately $46,000 for the three months ended March 31, 2014. This increase in interest income is due to higher cash and cash equivalents and marketable securities balances and using longer-term higher yielding investments.  

Liquidity and Capital Resources

The following table summarizes our liquidity and capital resources as of March 31, 2015, and is intended to supplement the more detailed discussion that follows:

 

Liquidity and capital resources (in thousands)

 

March 31, 2015

 

 

December 31, 2014

 

Cash and cash equivalents

 

$

155,466

 

 

$

38,539

 

Marketable securities

 

 

154,863

 

 

 

102,788

 

Working capital

 

 

290,609

 

 

 

104,938

 

Stockholders' equity

 

 

304,336

 

 

 

117,048

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

 

 

Three Months

 

 

 

Ended

 

 

Ended

 

 

 

March 31, 2015

 

 

March 31, 2014

 

Cash provided by (used in):

 

 

 

 

 

 

 

 

Operating activities

 

$

(50,023

)

 

$

(17,047

)

Investing activities

 

 

(52,683

)

 

 

7,943

 

Financing activities

 

 

219,633

 

 

 

129,440

 

Increase in cash and cash equivalents

 

$

116,927

 

 

$

120,336

 

Operating Activities:

For the three months ended March 31, 2015 and March 31, 2014, we reported net loss of approximately $52.5 million and $19.8 million, respectively, and cash flows used in operating activities of approximately $50.0 million and $17.0 million, respectively.  Included in the approximately $50.0 million cash used in operating activities in the quarter ended March 31, 2015, was an employee payroll tax payment of approximately $16.4 million related to the exercise of stock options by employees.  The taxes withheld by the stockbroker were received by us during the last week of December 2014 and transmitted to the various taxing authorities in January 2015.  The remaining approximately $33.6 million of cash used in operating activities reflects the increased cost associated with expanding our clinical trials and in preparing for the filing of an NDA in the first quarter of 2016.  

16

 


 

For the three months ended March 31, 2015, the net cash used in operating activities, noted above, consisted of approximately $20.5 million of non-cash items such as depreciation and stock option expense and a decrease of approximately $0.1 million in prepaid expenses and other assets due to the use of comparator drugs for use in our clinical trials, an increase in the liability for deferred rent of approximately $0.2 million and a decrease in accrued expenses and accounts payable of approximately $18.4 million during the three months ended March 31, 2015, of which approximately $16.4 million is related to the payment of payroll taxes withheld for options exercised.

For the three months ended March 31, 2014, the net cash used in operating activities, noted above, consisted of approximately $5.3 million of non-cash items such as depreciation and stock option expense, and an increase in accounts payable and accrued expenses of approximately $1.0 million. Further increasing the net loss to arrive at the net cash used in operating activities was an increase in licensor receivable of approximately $3.5 million which was reversed when the amended license agreement was signed in July 2014. Prepaid expenses and other assets increased approximately $0.1 million due to the purchase of comparator drugs for use in our clinical trials.

Investing Activities:

During the three months ended March 31, 2015, net cash used in investing activities was approximately $52.7 million compared to net cash received from investing activities of approximately $7.9 million for the same period in 2014. The approximately $52.7 million was made up of approximately $104.8 million used for investments of excess cash made in accordance with our investment policy, offset by $52.8 million cash received from investments that matured and approximately $0.4 million used to purchase property and equipment.  For the three months ended March 31, 2014, the net cash received from investing activities consisted of approximately $8.2 million received from the maturity of available-for-sale securities, offset by $0.2 million used to purchase property and equipment.

Financing Activities:

During the three months ended March 31, 2015, we received net proceeds of approximately $205.2 million from the closing of the January 2015 public offering of our common stock, compared to approximately $129.4 million received from the closing of the February 2014 public offering of our common stock during the same period in 2014. During the three months ended March 31, 2015, we received proceeds from the exercise of stock options of approximately $14.4 million.

Current and Future Financing Needs:

We have incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical trials and our R&D efforts. Given the current and desired pace of clinical development of our product candidates, over the next 12 months we estimate that our R&D spending will be approximately $115 million to $130 million, excluding stock-based compensation. We anticipate spending approximately $10 million to $12 million for general and administrative expenses over the next 12 months, excluding stock-based compensation. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control.

While we believe that the approximately $310.3 million in cash, cash equivalents and marketable securities and the $1.8 million licensor receivable as of March 31, 2015, will be sufficient to enable us to meet our anticipated expenditures through 2016 and into 2017, we may seek to obtain additional capital through the sale of debt or equity securities, if necessary, especially in conjunction with opportunistic acquisitions or licensing arrangements. We expect to continue incurring significant losses for the foreseeable future and our continuing operations will depend on whether we are able to raise additional funds through additional equity or debt financing or by entering into a strategic alliance with a third party concerning one or more of our product candidates. Through March 31, 2015, a significant portion of our financing has been through public offerings and private placements of our equity securities. We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can give no assurances that any additional capital raised will be sufficient to meet our needs. Further, in light of current economic conditions, including the lack of access to the capital markets being experienced by small companies, particularly in our industry, there can be no assurance that such capital will be available to us on favorable terms or at all. If we are unable to raise additional funds in the future, we may be forced to delay or discontinue the development of one or more of our product candidates and forego attractive business opportunities. Any additional sources of financing will likely involve the sale of our equity securities, which will have a dilutive effect on our stockholders.

In addition, we have based our estimate of funding our capital requirements on assumptions that may prove to be wrong. We may need to obtain additional funds sooner than planned or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of equity or debt and other sources of funds. We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms

17

 


 

that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interests of our existing stockholders will be diluted. If we are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly limit our operations, and our business, financial condition and results of operations would be materially harmed. In such an event, we would be required to undertake a thorough review of our programs, and the opportunities presented by such programs, and allocate our resources in the manner most prudent.

Non-GAAP Financial Measures:

In addition to our operating results, as calculated in accordance with the accounting principles generally accepted in the United States, or GAAP, we use certain non-GAAP financial measures when planning, monitoring, and evaluating our operational performance. The following table presents our net loss and net loss per share, as calculated in accordance with GAAP, as adjusted to remove the impact of employee stock-based compensation. These non-GAAP financial measures are not, and should not be viewed as, substitutes for GAAP reporting measures. We believe these non-GAAP measures enhance understanding of our financial performance, are more indicative of our operational performance and facilitate a better comparison among fiscal periods.

For the three months ended March 31, 2015, stock-based compensation represented approximately 38.3% of our loss from operations, compared to 26.1% for the three months ended March 31, 2014. This cost is related to our employee hiring practice and the fair market value of the stock option grants on the day granted.

 

 

 

18

 


 

Reconciliation of GAAP Net Loss to Non-GAAP Adjusted Net Loss and

GAAP Net Loss Per Share to Non-GAAP Adjusted Net Loss Per Share

(in thousands except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

 

 

2015

 

 

2014

 

 

GAAP net loss

 

$

(52,454

)

 

$

(19,794

)

 

Adjustments:

 

 

 

 

 

 

 

 

 

Stock-based compensation -

 

 

 

 

 

 

 

 

 

General and administrative

 

 

4,704

 

 

 

1,341

 

(1)

Research and development

 

 

15,399

 

 

 

3,822

 

(2)

Non-GAAP adjusted net loss

 

$

(32,351

)

 

$

(14,631

)

 

 

 

 

 

 

 

 

 

 

 

GAAP net loss per sharebasic and diluted

 

$

(1.66

)

 

$

(0.67

)

 

Adjustment to net loss (as detailed above)

 

 

0.64

 

 

 

0.17